Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB. Through the use of high throughput whole cell screening of an extensive compound library a number of imidazo[1,2-a]pyridine (IP) compounds were obtained as potent lead molecules active against M. tuberculosis and Mycobacterium bovis BCG. The IP inhibitors (1-4) demonstrated minimum inhibitory concentrations (MICs) in the range of 0.03 to 5 µM against a panel of M. tuberculosis strains. M. bovis BCG spontaneous resistant mutants were generated against IP 1, 3, and 4 at 5× MIC and subsequent whole genome sequencing identified a single nucleotide polymorphism (937)ACC>(937)GCC (T313A) in qcrB, which encodes the b subunit of the electron transport ubiquinol cytochrome C reductase. This mutation also conferred cross-resistance against IP 1, 3 and 4 demonstrating a common target. Gene dosage experiments confirmed M. bovis BCG QcrB as the target where over-expression in M. bovis BCG led to an increase in MIC from 0.5 to >8 µM for IP 3. An acute murine model of TB infection established bacteriostatic activity of the IP series, which await further detailed characterization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The QcrB subunit has been recently shown to be the target of novel imidazo[1,2-a]pyridine inhibitors that are active against M. tuberculosis at low micromolar concentrations (73).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 1×
“Aligned BAM files were supplied as input to the samtools mpileup command using the command-line modifiers ‘‘-C50 -D -S –E’’ and otherwise default settings [30].”
MethodFast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Woese, C. R. (1987) · Microbiological Reviews · doi:10.1128/mr.51.2.221-271.1987 · Cited by 5,042
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544 · cited 2×
“According to TraSH analysis, qcrB is an essential gene [35,36,37].”
BackgroundA Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 2×
“identified utilizing a whole cell phenotypic HTS campaign of a library of more than 70,000 compounds against Mycobacterium smegmatis [11,12,13].”
MethodPossible molecular mechanisms of the protonmotive function of cytochrome systems
Mitchell, P. (1976) · Journal of Theoretical Biology · doi:10.1016/0022-5193(76)90124-7 · Cited by 1,268 · cited 1×
“as it functions by binding to the Qi site, proximal to the BH heme, inhibiting oxidation of the cytochrome b subunit [50].”
BackgroundThe challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042 · cited 2×
“era where TB is untreatable, the discovery of unique drug targets and novel inhibitory compounds can be considered invaluable in terms of meeting the current and future therapeutic needs to relieve the burden of TB cases worldwide [4].”
BackgroundCrystal Structure of the Cytochrome bc 1 Complex from Bovine Heart Mitochondria
Xia, D., Yu, C.-A., Kim, H., Xia, J.-Z., Kachurin, A. M., Zhang, L., Yu, L., & Deisenhofer, J. (1997) · Science · doi:10.1126/science.277.5322.60 · Cited by 946 · cited 1×
“the structure of a myxothiazol-bound cytochrome bc1 complex [51] found the substitution did not fall within the myxothiazol”
BackgroundComprehensive identification of conditionally essential genes in mycobacteria
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231275498 · Cited by 616 · cited 2×
“According to TraSH analysis, qcrB is an essential gene [35,36,37].”
Background
Cited by
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Twenty years of bacterial genome sequencing
Loman, N. J., & Pallen, M. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3565 · Cited by 344
Self-citationNew agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target
ABRAHAMS, K. A., & BESRA, G. S. (2018) · Parasitology · doi:10.1017/s0031182016002377 · Cited by 227
“Phenotypic HTS can reveal anti-TB agents with whole-cell activity and unknown modes of action, having the potential to unveil new biochemical pathways (Abrahams et al. 2012, 2016; Gurcha et al. 2014; Mugumbate et al. 2015).”
Self-citationBald, D., Villellas, C., Lu, P., & Koul, A. (2017) · mBio · doi:10.1128/mbio.00272-17 · Cited by 219
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
“The QcrB subunit has been recently shown to be the target of novel imidazo[1,2-a ]pyridine inhibitors that are active against M. tuberculosis at low micromolar concentrations (73).”
BackgroundKalia, N. P., Hasenoehrl, E. J., Ab Rahman, N. B., Koh, V. H., Ang, M. L. T., Sajorda, D. R., Hards, K., Grüber, G., Alonso, S., Cook, G. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706139114 · Cited by 188
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1
Rybniker, J., Vocat, A., Sala, C., Busso, P., Pojer, F., Benjak, A., & Cole, S. T. (2015) · Nature Communications · doi:10.1038/ncomms8659 · Cited by 191
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Mdluli, K., Kaneko, T., & Upton, A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021154 · Cited by 180
Kang, S., Kim, R. Y., Seo, M. J., Lee, S., Kim, Y. M., Seo, M., Seo, J. J., Ko, Y., Choi, I., Jang, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003606 · Cited by 178
Tuberculosis drug discovery in the post‐post‐genomic era
Lechartier, B., Rybniker, J., Zumla, A., & Cole, S. T. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201201772 · Cited by 176
“Using this system, Abrahams et al generated conditional Mtb knock-down mutants of the essential panC gene, which encodes pantothenate synthase (Abrahams et al , 2012a).”
Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis
Black, P. A., Warren, R. M., Louw, G., van Helden, P. D., Victor, T. C., & Kana, B. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02293-13 · Cited by 172
Beites, T., O’Brien, K., Tiwari, D., Engelhart, C. A., Walters, S., Andrews, J., Yang, H.-J., Sutphen, M. L., Weiner, D. M., Dayao, E. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12956-2 · Cited by 136
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
Campaniço, A., Moreira, R., & Lopes, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.020 · Cited by 146
Cook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0014-2016 · Cited by 141
Arora, K., Ochoa‐Montaño, B., Tsang, P. S., Blundell, T. L., Dawes, S. S., Mizrahi, V., Bayliss, T., Mackenzie, C. J., Cleghorn, L. A. T., Ray, P. C., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03486-14 · Cited by 138
Energetics of Pathogenic Bacteria and Opportunities for Drug Development
Cook, G. M., Greening, C., Hards, K., & Berney, M. (2014) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2014.08.001 · Cited by 147
Tantry, S. J., Markad, S. D., Shinde, V. N., Bhat, J., Balakrishnan, G., Gupta, A. K., Ambady, A., Raichurkar, A. V., Kedari, C. K., Sharma, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01358 · Cited by 131
Lu, P., Heineke, M. H., Koul, A., Andries, K., Cook, G. M., Lill, H., van Spanning, R., & Bald, D. (2015) · Scientific Reports · doi:10.1038/srep10333 · Cited by 119
ATP synthase in mycobacteria: Special features and implications for a function as drug target
Lü, P., Lill, H., & Bald, D. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.01.022 · Cited by 130
Moraski, G. C., Markley, L. D., Cramer, J. W., Hipskind, P. A., Boshoff, H. I., Bailey, M. A., Alling, T., Ollinger, J., Parish, T., & Miller, M. J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400088y · Cited by 112
Whole-genome sequencing targets drug-resistant bacterial infections
Punina, N. V., Makridakis, N. M., Remnev, M. A., & Topunov, A. F. (2015) · Human Genomics · doi:10.1186/s40246-015-0037-z · Cited by 110
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening
Manjunatha, U. H., & Smith, P. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.031 · Cited by 111
Hit Generation in TB Drug Discovery: From Genome to Granuloma
Yuan, T., & Sampson, N. S. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00602 · Cited by 110
Identification of KasA as the cellular target of an anti-tubercular scaffold
Abrahams, K. A., Chung, C., Ghidelli, S., Rullás, J., Rebollo-López, M. J., Gurcha, S. S., Cox, J. A. G., Mendoza-Losana, A., Jiménez‐Navarro, E., Martínez, M. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12581 · Cited by 99
Self-citationDual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013207 · Cited by 97
Goldman, R. C. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.09.003 · Cited by 102
Tang, J., Wang, B., Wu, T. S., Wan, J., Tu, Z., Njire, M. M., Wan, B., Franzblauc, S. G., Zhang, T., Lu, X., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00176 · Cited by 97
Drug resistance mechanisms and novel drug targets for tuberculosis therapy
Islam, M. M., Hameed, H. M. A., Mugweru, J., Chhotaray, C., Wang, C., Tan, Y., Liu, J., Li, X., Tan, S., Ojima, I., et al. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.10.002 · Cited by 102
Lü, P., Asseri, A. H., Kremer, M., Maaskant, J. J., Ummels, R., Lill, H., & Bald, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-20989-8 · Cited by 98
van der Westhuyzen, R., Winks, S., Wilson, C. R., Boyle, G. A., Gessner, R. K., de Melo, C. S., Taylor, D., de Kock, C. A., Njoroge, M., Brunschwig, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01542 · Cited by 85
Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor
Martínez-Hoyos, M., Pérez‐Herrán, E., Gülten, G., Encinas, L., Álvarez-Gómez, D., Álvarez, E. F., Ferrer, S. B., García-Pérez, A., Ortega, F., Angulo‐Barturen, Í., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.006 · Cited by 91
Self-citationArrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB
Moraski, G. C., Seeger, N., Miller, P. A., Oliver, A. G., Boshoff, H. I., Cho, S., Mulugeta, S., Anderson, J. R., Franzblau, S. G., & Miller, M. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00154 · Cited by 82
The Expanding Diversity of Mycobacterium tuberculosis Drug Targets
Wellington, S., & Hung, D. T. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00255 · Cited by 87
Recent developments of imidazo[1,2- a ]pyridine analogues as antituberculosis agents
Samanta, S., Kumar, S., Aratikatla, E. K., Ghorpade, S. R., & Singh, V. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00019b · Cited by 88
Foo, C. S.-Y., Lupien, A., Kienle, M., Vocat, A., Benjak, A., Sommer, R., Lamprecht, D. A., Steyn, A. J. C., Pethe, K., Piton, J., et al. (2018) · mBio · doi:10.1128/mbio.01276-18 · Cited by 78
Identification and validation of novel drug targets in Mycobacterium tuberculosis
Singh, V., & Mizrahi, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.010 · Cited by 89
Batt, S. M., Cacho, M., Castro‐Pichel, J., Stubbs, C. J., Peral, L. V.-G. D., Pérez‐Herrán, E., Dhar, N., Mouzon, B., Rees, M., Hutchinson, J. P., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00065 · Cited by 70
Self-citationTHPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria
Cox, J. A. G., Abrahams, K. A., Alemparte, C., Ghidelli, S., Rullás, J., Angulo‐Barturen, Í., Singh, A., Gurcha, S. S., Nataraj, V., Bethell, S., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2015.6 · Cited by 73
Self-citationInhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria
Lee, B. S., Kalia, N. P., Jin, X., Hasenoehrl, E., Berney, M., & Pethe, K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005732 · Cited by 72
Chandrasekera, N. S., Berube, B. J., Shetye, G. S., Chettiar, S. N., O’Malley, T., Manning, A. J., Flint, L., Awasthi, D., Ioerger, T. R., Sacchettini, J. C., et al. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00112 · Cited by 65
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iqbal, I., Bajeli, S., Akela, A. K., & Kumar, A. (2018) · Pathogens · doi:10.3390/pathogens7010024 · Cited by 68
Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3
Degiacomi, G., Belardinelli, J. M., Pasca, M. R., Rossi, E. D., Riccardi, G., & Chiarelli, L. R. (2020) · Applied Sciences · doi:10.3390/app10020623 · Cited by 64
Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease
Veale, C. G. L. (2019) · ChemMedChem · doi:10.1002/cmdc.201800755 · Cited by 66
Cleghorn, L. A. T., Ray, P. C., Odingo, J. O., Kumar, A., Wescott, H., Korkegian, A., Masquelin, T., Moure, A. L., Wilson, C., Davis, S. H., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00172 · Cited by 59
Bactericidal Activity of an Imidazo[1, 2-a]pyridine Using a Mouse M. tuberculosis Infection Model
Cheng, Y., Moraski, G. C., Cramer, J. W., Miller, M. J., & Schorey, J. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087483 · Cited by 58
Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface
Abrahams, K. A., Cox, J. A. G., Fütterer, K., Rullás, J., Ortega-Muro, F., Loman, N. J., Moynihan, P. J., Pérez‐Herrán, E., Jiménez, E., Esquivias, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09642-y · Cited by 59
Self-citationBioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
Hasenoehrl, E., Wiggins, T. J., & Berney, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.611683 · Cited by 61
Inhibiting Mycobacterium tuberculosis within and without
Cole, S. T. (2016) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2015.0506 · Cited by 61
The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents
Zuniga, E. S., Korkegian, A., Mullen, S., Hembre, E. J., Ornstein, P. L., Cortez, G. S., Biswas, K., Kumar, N., Cramer, J. W., Masquelin, T., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.030 · Cited by 55
Foo, C. S.-Y., Pethe, K., & Lupien, A. (2020) · Applied Sciences · doi:10.3390/app10072339 · Cited by 61
New structural classes of antituberculosis agents
Kumar, V., Patel, S. R., & Jain, R. (2017) · Medicinal Research Reviews · doi:10.1002/med.21454 · Cited by 56
Mascolo, L., & Bald, D. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.002 · Cited by 58
Moraski, G. C., Oliver, A. G., Markley, L. D., Cho, S., Franzblau, S. G., & Miller, M. J. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.062 · Cited by 52
Hong, W. D., Gibbons, P. D., Leung, S. C., Amewu, R. K., Stocks, P. A., Stachulski, A. V., Horta, P., Cristiano, M. L. S., Shone, A. E., Moss, D. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01718 · Cited by 55
“Targeting components of the Mtb respiratory chain (Figure 2) has been shown by us and other laboratories, to be effective in sterilizing both replicating and dormant Mtb.(9-18) The initial target”
BackgroundInfluentialMoraski, G. C., Miller, P. A., Bailey, M. A., Ollinger, J., Parish, T., Boshoff, H. I., Cho, S., Anderson, J. R., Mulugeta, S., Franzblau, S. G., et al. (2014) · ACS Infectious Diseases · doi:10.1021/id500008t · Cited by 52
Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels
O’Malley, T., Alling, T., Early, J. V., Wescott, H., Kumar, A., Moraski, G. C., Miller, M. J., Masquelin, T., Hipskind, P. A., & Parish, T. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02439-17 · Cited by 52
Tuberculosis drug discovery and emerging targets
Mdluli, K. E., Kaneko, T., & Upton, A. M. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12459 · Cited by 51
Future target-based drug discovery for tuberculosis?
Kana, B. D., Karakousis, P. C., Parish, T., & Dick, T. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.10.003 · Cited by 53
Endless resistance. Endless antibiotics?
Fisher, J. F., & Mobashery, S. (2015) · MedChemComm · doi:10.1039/c5md00394f · Cited by 47
Mugumbate, G., Abrahams, K. A., Cox, J. A. G., Papadatos, G., van Westen, G. J. P., Lelièvre, J., Calus, S., Loman, N. J., Ballell, L., Barros, D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121492 · Cited by 51
“The generation of spontaneous resistant mutants and WGS was conducted as described in [30].”
Self-citationRebollo-López, M. J., Lelièvre, J., Álvarez-Gómez, D., Castro‐Pichel, J., Martínez-Jiménez, F., Papadatos, G., Kumar, V. D., Colmenarejo, G., Mugumbate, G., Hurle, M. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142293 · Cited by 47
Self-citationWu, Z., Lu, Y., Li, L., Zhao, R., Wang, B., Lv, K., Liu, M., & You, X. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00330 · Cited by 45
Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203
Kang, S., Kim, Y. M., Kim, R. Y., Seo, M. J., No, Z., Nam, K., Kim, S., & Kim, J. C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.082 · Cited by 44
Wang, A., Lv, K., Li, L., Liu, H., Tao, Z., Wang, B., Liu, M., Ma, C., Ma, X., Han, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.038 · Cited by 44
Moraski, G. C., Deboosère, N., Marshall, K. L., Weaver, H. A., Vandeputte, A., Hastings, C., Woolhiser, L. K., Lenaerts, A. J. M., Brodin, P. M., & Miller, M. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227224 · Cited by 44
Identification of active molecules againstMycobacterium tuberculosisthrough machine learning
Ye, Q., Chai, X., Jiang, D., Liu, Y., Shen, C., Zhang, X., Li, D., Cao, D., & Hou, T. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab068 · Cited by 60
Dunn, E. A., Roxburgh, M., Larsen, L., Smith, R. A. J., McLellan, A. D., Heikal, A., Murphy, M. P., & Cook, G. M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.050 · Cited by 53
Phummarin, N., Boshoff, H. I., Tsang, P. S., Dalton, J. P., Wiles, S., rd, C. E. B., & Copp, B. R. (2016) · MedChemComm · doi:10.1039/c6md00236f · Cited by 43
Lv, K., Li, L., Wang, B., Liu, M., Wang, B., Shen, W., Guo, H., & Lu, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.044 · Cited by 43
Berube, B. J., & Parish, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-17 · Cited by 47
The Anti-Tuberculosis Agents Under Development and the Challenges Ahead
Kumar, D., Negi, B., & Rawat, D. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.128 · Cited by 47
Kim, M.-S., Jang, J., Rahman, N. B. A., Pethe, K., Berry, E. A., & Huang, L.-S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624312 · Cited by 46
Berube, B. J., Russell, D., Castro, L., Choi, S., Narayanasamy, P., & Parish, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02661-18 · Cited by 43
Evans, J. C., & Mizrahi, V. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00812 · Cited by 50
Trofimov, V., Kicka, S., Mucaria, S., Hanna, N., Ramón, F., Peral, L. V.-G. D., Lelièvre, J., Ballell, L., Scapozza, L., Besra, G. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22228-6 · Cited by 36
Self-citationWang, H., Wang, A., Gu, J. H., Fu, L., Lv, K., Ma, C., Tao, Z., Wang, B., Liu, M., Guo, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.071 · Cited by 40
Abrahams, K. A., & Besra, G. S. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00261e · Cited by 44
Self-citationTerminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?
Bajeli, S., Baid, N., Kaur, M., Pawar, G. P., Chaudhari, V. D., & Kumar, A. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.589318 · Cited by 44
Harrison, G. A., Bridwell, A. E. M., Singh, M., Jayaraman, K., Weiss, L. A., Kinsella, R. L., Aneke, J. S., Flentie, K., Schene, M. E., Gaggioli, M. R., et al. (2019) · mSphere · doi:10.1128/msphere.00606-19 · Cited by 45
Wall, R. J., Carvalho, S., Milne, R., Bueren‐Calabuig, J. A., Moniz, S., Cantizani-Perez, J., MacLean, L. M., Kessler, A., Cotillo, I., Sastry, L., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00426 · Cited by 41
QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents
Bahuguna, A., Rawat, S., & Rawat, D. S. (2021) · Medicinal Research Reviews · doi:10.1002/med.21779 · Cited by 39
Lü, P., Villellas, C., Koul, A., Andries, K., Lill, H., & Bald, D. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.74 · Cited by 33
Gurcha, S. S., Usha, V., Cox, J. A. G., Fütterer, K., Abrahams, K. A., Bhatt, A., Alderwick, L. J., Reynolds, R. C., Loman, N. J., Nataraj, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113568 · Cited by 36
“6 mM) by plating 10(8) cells on solid media as described previously [23,26].”
Self-citationSmall organic molecules targeting the energy metabolism of Mycobacterium tuberculosis
Urban, M., Šlachtová, V., & Brulíková, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113139 · Cited by 37
Nandikolla, A., Srinivasarao, S., Khetmalis, Y. M., Kumar, B. K., Murugesan, S., Shetye, G. S., Ma, R., Franzblau, S. G., & Sekhar, K. V. G. C. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105137 · Cited by 33
Jeffreys, L. N., Ardrey, A., Hafiz, T. A., Dyer, L.-A., Warman, A. J., Mosallam, N., Nixon, G. L., Fisher, N. E., Hong, W. D., Leung, S. C., et al. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00283 · Cited by 35
Molecular Mechanisms of MmpL3 Function and Inhibition
Williams, J. T., & Abramovitch, R. B. (2023) · Microbial Drug Resistance · doi:10.1089/mdr.2021.0424 · Cited by 36
Reddyrajula, R., & Dalimba, U. (2019) · New Journal of Chemistry · doi:10.1039/c9nj03462e · Cited by 32
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc 1
Braillard, S., Keenan, M., Breese, K. J., Heppell, J., Abbott, M. J., Islam, R., Shackleford, D. M., Katneni, K., Crighton, E., Chen, G., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh9902 · Cited by 31
“Drugs targeting the cytochrome bc 1 complex are in clinical use for treatment of malaria and fungal pneumonia, and cytochrome bc 1 complex was also reported as a promising target for treatment of tuberculosis ( 17 – 19 ).”
BackgroundFarhat, M. R., Shapiro, B. J., Sheppard, S. K., Colijn, C., & Murray, M. B. (2014) · Genome Medicine · doi:10.1186/s13073-014-0101-7 · Cited by 34
“[31] 2013 - Identify resistance targets(s) for novel imidazole No Yes: spontaneous mutants resistant to drug and their sensitive ancestor Identification of all mutations Yes qcrb”
BackgroundMoraski, G. C., Cheng, Y., Cho, S., Cramer, J. W., Godfrey, A. G., Masquelin, T., Franzblau, S. G., Miller, M. J., & Schorey, J. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00618-16 · Cited by 31
Xu, Z. H., Zhou, A., Wu, J., Zhou, A., Li, J., Zhang, S., Wu, W., Karakousis, P. C., & Yao, Y.-F. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02895 · Cited by 31
Grover, S., Engelhart, C. A., Pérez‐Herrán, E., Li, W., Abrahams, K. A., Papavinasasundaram, K. G., Bean, J. M., Sassetti, C. M., Mendoza-Losana, A., Besra, G. S., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00675 · Cited by 24
Self-citationTherapeutic potential of promiscuous targets in Mycobacterium tuberculosis
Lee, B. S., & Pethe, K. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.06.006 · Cited by 26
Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets
Fernandes, G., Jornada, P. D., de Souza, C. O., Chin, C. M., Pavan, F. R., & dos Santos, J. L. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150818103836 · Cited by 30
Bouvier, G., Simenel, C., Jang, J., Kalia, N. P., Choi, I., Nilges, M., Pethe, K., & Izadi‐Pruneyre, N. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00975 · Cited by 27
Roy, K. K., & Wani, M. A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696771 · Cited by 25
Alsayed, S. S. R., Lun, S., Bailey, A. W., Suri, A., Huang, C., Mocerino, M., Payne, A. D., Sredni, S. T., Bishai, W. R., & Gunosewoyo, H. (2021) · RSC Advances · doi:10.1039/d0ra10728j · Cited by 27
Beteck, R. M., Seldon, R., Jordaan, A., Warner, D. F., Hoppe, H. C., Laming, D., & Khanye, S. D. (2019) · Molecules · doi:10.3390/molecules24091740 · Cited by 24
Metadata
- Authors
- Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., Ballell, L., & Besra, G. S.
- Affiliations
- University of Birmingham (GB)
- GlaxoSmithKline (Spain) (ES)
- Corresponding author
- Besra, Gurdyal S.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-31
- Volume
- 7
- Issue
- 12
- Pages
- e52951
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3534098
- OpenAlex
- W1974074976
- Cited by
- 177
- References
- 53
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 11 · 2020: 18 · 2019: 16 · 2018: 17 · 2017: 16 · 2016: 19 · 2015: 22 · 2014: 20 · 2013: 3
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (acceptedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Funders
- University of Warwick
- European Commission (261378, 2007–2013, FP7 2007-2013)
- Biotechnology and Biological Sciences Research Council (1112080)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Biological Evaluation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- imidazo[1,2-a]pyridines, Mycobacterium tuberculosis, Mycobacterium bovis BCG, drug resistance, cross-resistance, gene dosage, lead compound identification, murine tuberculosis model, tuberculosis drug discovery
- MeSH terms
- Animals, Antitubercular Agents, Dogs, Humans, Microbial Sensitivity Tests, Microsomes, Liver, Mycobacterium bovis, Mycobacterium tuberculosis, Pyridines, Tuberculosis, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.